Key clinical point: Postmenopausal women with osteoporosis who were treated with abaloparatide did not suffer from increased risk of cardiovascular events.

Major finding: The percentage of patients with serious cardiac adverse events was similar across the three study groups (1% for abaloparatide, 1% for teriparatide, 0.9% for placebo).

Study details: An analysis of data from the randomized, double-blind, multicenter Abaloparatide Comparator Trial in Vertebral Endpoints trial, its extension study, and an additional pharmacology study.

Disclosures: The analysis was partially funded by Radius Health. Its authors acknowledged numerous potential conflicts of interest, including receiving grants and research support from various organizations and pharmaceutical companies.